Tcon stock press release

Tracon Pharmaceuticals, Inc. - TCON - Stock Price Today ... View TRACON Pharmaceuticals, Inc. TCON investment & stock information. Get the latest TRACON Pharmaceuticals, Inc. TCON detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Press Releases :: Cocrystal Pharma, Inc. (COCP) Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market. March 11, 2020 TRACON Pharmaceuticals Announces $15 Million Common Stock ... Oct 21, 2019 · This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in Press Releases - CNBC Latest news hot off the presses from CNBC. More In Press Releases. CNBC and SurveyMonkey Release Results of Inaugural "Women at Work" Survey. TCON Stock Price, Forecast & News (TRACON Pharmaceuticals)

Top NASDAQ:TCON Bull/Bear Pitches. The best Bull and Bear pitches based on recency and number of recommendations. zzlangerhans (99.66). Submitted 

Learn about TCON with our data and independent analysis including price, star rating, valuation, dividends, and financials. Start a 14-day free trial to  TCON / TRACON Pharmaceuticals, Inc. Institutional Ownership These institutions hold a total of 5,388,536 shares. ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Third Quarter 2019 Earnings Conference Call. Get today's TRACON Pharmaceuticals Inc stock price and latest TCON news as well as TRACON Pharma real-time stock Next Earnings DateMay 06, 2020. View live TRACON PHARMACEUTICALS INC chart to track its stock's price action. Edited Transcript of TCON earnings conference call or presentation 

OTC Markets | TCON

22 Mar 2020 This from their November earnings update The Phase 2 POC data from the Phase 1/2 clinical trial of TRC253 in metastatic castrate resistant  View the latest TRACON Pharmaceuticals Inc. (TCON) stock price, news, TCON has not issued dividends in more than 1 year. 03/19/20; Press Release. San Diego, CA – November 5, 2019 – TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development   1 Year % Chg -87.84. Market Cap 9.1M. Shares Outstanding 5.4M. Beta 2.07. Dividend (Yield) -. Div Amount -. Ex Div Date -. Earnings Date 2020-05-12. View a financial market summary for TCON including stock price quote, trading volume, All·Press Releases·Headlines Stock Price & Volume | Full Chart. Introducing TRACON Pharmaceuticals (NASDAQ:TCON), The Stock That High Growth Earnings: TCON is forecast to remain unprofitable over the next 3 years 

Tracon Pharmaceuticals, Inc. TCON Stock Message Board: [b]$TCON recent news/filings[/b]

TRACON Pharmaceuticals, Inc. Common Stock (TCON) Stock ... TRACON Pharmaceuticals, Inc. Common Stock (TCON) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Press Release • Mar 19, 2020. PRESS RELEASES | TRACON Pharmaceuticals Inc

View the latest TRACON Pharmaceuticals Inc. (TCON) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The Investor Relations website contains information about TRACON Pharmaceuticals Inc's business for stockholders, potential investors, and financial analysts. TCON | TRACON Pharmaceuticals Inc. Stock Price & News - WSJ View the latest TRACON Pharmaceuticals Inc. (TCON) stock price, news, historical charts, analyst ratings and financial information from WSJ. TRACON Pharmaceuticals, Inc. (TCON) Stock Price, Quote ... Find the latest TRACON Pharmaceuticals, Inc. (TCON) stock quote, history, news and other vital information to help you with your stock trading and investing. TRACON Pharmaceuticals Announces Reverse Stock Split ...

Biotech Stock Catalyst and FDA Calendar for your biotech stock investing. Use our tools on your road to profit in the stock market. Biotech stocks with key binary events/catalysts - FDA Approval/PDUFA dates, Advisory Committee and Phase 2 & 3 trial data releases dates are noted. Current Report Filing (8-k) - Investors Hub